United States medical practice summary: Innovative off-label medication use

American Journal of Medical Quality

Volumn 21, Issue 4, 2006, Pages 246-254

  Ansani, Nicole ^a   Branch, Robert ^d   Fedutes Henderson, Bethany ^b   Smitherman, Thomas ^e   Weber, Robert J ^c   Skledar, Susan ^c   Zgheib, Nathalie ^d   Sirio, Carl ^f  

^a PFIZER INC   (United States)

^b Rite Aid   (United States)

^c Department of Pharmacy and Therapeutics ^*

^d Center for Clinical Pharmacology   (United States)

^e Division of Cardiology   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Drug use; Innovative off label; Medication safety; Medication use; Off label

Indexed keywords

DRUG;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG LABELING; DRUG THERAPY; HUMAN; MANAGEMENT; PHARMACY; UNITED STATES;

CROSS-SECTIONAL STUDIES; DRUG LABELING; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; PRACTICE MANAGEMENT, MEDICAL; UNITED STATES;

EID: 33745841912     PISSN: 10628606     EISSN: 1555824X     Source Type: Journal    
DOI: 10.1177/1062860606288346     Document Type: Article

References (17)

1. US Food and Drug Administration. "Off-label" and investigational use of marketed drugs, biologies, and medical devices: guidance for institutional review boards and clinical investigators 1998 update. Available at: http://www.fda.gov/oc/ohrt/irbs/offlabel.html. Accessed July 26, 2005.
2. Henry V. Off-label prescribing: legal implications. J Leg Med. 1999;20:365-383.
3. Blum RS. Legal considerations in off-label medication prescribing. Arch Intern Med. 2002;162:1777-1779.
4. Cohen PJ. "Off-label" use of prescription drugs: legal, clinical and policy considerations. Eur J Anaesthesiol. 1997;14:231-235.
5. Zindrick MR, Bunch WH. Orthopaedic surgery and Food and Drug Administration off-label uses. Clin Orthop. 2000;(378):31-38.
6. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications and safety. Drug Safety. 2002;25:1-5.
7. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665-670.
8. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999;85:965-968.
9. Conroy S. Unlicensed and off-label drug use: issues and recommendations. Pediatr Drugs. 2002;4:353-359.
10. Association of American Medical Colleges. Council of Teaching Hospitals and Health Systems alphabetical listing. Available at: http://www.aamc.org/ members/listings/thalpha. htm. Accessed January 5, 2004.
11. Mannebach MR, Ascione FJ, Gaither CA, Bagozzi RP, Cohen IRA, Ryan ML. Activities, functions, and structure of pharmacy and therapeutics committees in large teaching hospitals. Am J Health Syst Pharm. 1999;56:622-628.
12. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing-2004. Am J Health Syst Pharm. 2005;62:378-390.
13. Ansani NT, Fedutes BF, Skledar SJ, et al. Practical approach to grading evidence for formulary recommendations. Am J Health Syst Pharm. 2005;62:1498-1501.
14. Office for Human Research Protections Web site. Available at: http://www.hhs.gov/ohrp. Accessed January 25, 2006.
15. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: US Department of Health, Education, and Welfare; 1979:7-14.
16. American Academy of Pediatrics. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration. Pediatrics. 1996;98:143-145.
17. American Academy of Pediatrics Committee on Drugs. Uses of drug not described in the package insert (off-label uses). Pediatrics. 2002;110:181-183.